Annual revenue rose from KRW 156 billion in 2022 to KRW 160.4 billion in 2023 (up 2.8% year on year) and KRW 171.8 billion in 2024 (up 7.1%), then fell 6.8% to KRW 160.1 billion in 2025. Among 2022 to 2025, 2024 was the largest year and 2022 the smallest.
An operating loss of KRW 14.8 billion in 2022 and KRW 20.2 billion in 2023 widened the deficit, before operating profit of KRW 11 billion in 2024 marked a turn to profit. Operating profit then fell 67.1% year on year to KRW 3.61 billion in 2025.
Operating margin ran at -9.5% in 2022, -12.6% in 2023, 6.4% in 2024 and 2.3% in 2025. Net profit attributable to controlling shareholders moved from a loss to KRW 8.7 billion in 2024 and back to a net loss of KRW 2.89 billion in 2025.
Net profit including non-controlling interests matched the controlling-shareholder figure in each year from 2022 to 2025. Operating cash flow was -KRW 3.2 billion in 2022, -KRW 7.22 billion in 2023, KRW 14 billion in 2024 and -KRW 4.14 billion in 2025.
Quarterly, an operating loss of KRW 1.47 billion in the third quarter of 2025 was followed by a KRW 109 million operating profit in the fourth quarter, but losses returned with KRW 1.71 billion in the first quarter of 2026, KRW 5 billion in the second and KRW 5.99 billion in the third.
Third-quarter 2026 revenue of KRW 29.3 billion fell 28.6% from the prior quarter and 14.0% from a year earlier. Net losses attributable to controlling shareholders over the last four quarters total KRW 19 billion. Past press reports linked the widening 2022 loss to botulinum toxin and microbiome R&D spending.
The drivers of the 2026 quarterly losses need to be traced through cost lines in the quarterly reports, and one-off items cannot be separated from the disclosed figures alone.